Sugi Predict

Sugi Predict / Compounds / SCHEMBL540725

SCHEMBL540725

SCHEMBL540725

NC1c2ccccc2CC1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ SIGMAR1 Q99720 2/20 0.42
▸ MMP3 P08254 1/20 0.42
▸ MMP8 P22894 1/20 0.42
▸ KDM1A O60341 4/20 0.42
▸ TSHR P16473 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTR2A P28223 1/20 0.39
▸ ANPEP P15144 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ EDNRB P24530 1/20 0.37
▸ EDNRA P25101 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8269273 1.00 MEN1 (0.43) MEN1KMT2ASIGMAR1MMP3MMP8
SCHEMBL15036610 1.00 MEN1 (0.43) MEN1KMT2ASIGMAR1MMP3MMP8
SCHEMBL29831499 1.00 MEN1 (0.43) MEN1KMT2ASIGMAR1MMP3MMP8
SCHEMBL29633476 1.00 MEN1 (0.43) MEN1KMT2ASIGMAR1MMP3MMP8
SCHEMBL16150008 1.00 MEN1 (0.43) MEN1KMT2ASIGMAR1MMP3MMP8
SCHEMBL16008920 1.00 MEN1 (0.43) MEN1KMT2ASIGMAR1MMP3MMP8
SCHEMBL6688800 1.00 MEN1 (0.43) MEN1KMT2ASIGMAR1MMP3MMP8
SCHEMBL4283038 0.85 KDM1A (0.42) SIGMAR1KDM1AGAAHTR2AANPEP
SCHEMBL4286040 0.85 KDM1A (0.42) SIGMAR1KDM1AGAAHTR2AANPEP
SCHEMBL19523452 0.84 KDM1A (0.41) SIGMAR1KDM1ATSHRNPSR1HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12077611-B2 Cyclic peptides multimers targeting α4β7 integrin ZEALAND PHARMA A/S (DK) 2024-09-03 — — US disclosed
US-20240209026-A1 A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS PROTAGONIST THERAPEUTICS, INC. (US) 2024-06-27 — — US disclosed
US-20230406884-A1 CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN ZEALAND PHARMA A/S (DK) 2023-12-21 — — US disclosed
US-11840581-B2 α4β7 thioether peptide dimer antagonists PROTAGONIST THERAPEUTICS, INC. (US) 2023-12-12 — — US disclosed
EP-3998260-B1 SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-11-01 — — EP disclosed
CN-116568658-A Rapid construction of tetrahydronaphthalenes, chromanes and indane motifs via cyclized C-H/C-H couplings 斯克里普斯研究学院 2023-08-08 — — CN disclosed
US-11713338-B2 Cyclic peptides multimers targeting α-4-β-7 integrin ZEALAND PHARMA A/S (DK) 2023-08-01 — — US disclosed
CN-109369635-B Compound or pharmaceutically acceptable salt thereof, application thereof and pharmaceutical composition 赛克里翁治疗有限公司 2023-06-30 — — CN disclosed
US-20230106002-A1 sGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. 2023-04-06 — — US disclosed
EP-4153310-A1 BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS F4 Pharma GmbH (AT) 2023-03-29 — — EP disclosed
EP-2970312-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME The Regents of The University of Michigan (US) 2016-01-20 — — EP disclosed
WO-2015176035-A1 α4β7 INTEGRIN THIOETHER PEPTIDE ANTAGONISTS PROTAGONIST THERAPEUTICS, INC. (US) 2015-11-19 — — WO disclosed
WO-2014164596-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-10-09 — — WO disclosed
US-20140256706-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2014-09-11 — — US disclosed
EP-2414350-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2012-02-08 — — EP disclosed
WO-2010117635-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-14 — — WO disclosed
WO-2008036449-A9 CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING UNIV CALIFORNIA (US) 2009-02-12 — — WO disclosed
WO-2008036449-A2 CHEMICAL ANTIBODIES FOR IMMUNOTHERAPY AND IMAGING THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-03-27 — — WO disclosed
WO-2004089362-A1 2-CYANOPYRROLES AND THEIR ANALOGUES AS DDP-IV INHIBITORS NOVO NORDISK A/S (DK) 2004-10-21 — — WO disclosed
EP-0189203-A2 Peptidylaminodiols ABBOTT LABORATORIES (US) 1986-07-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230106002-A1 sGC STIMULATORS PTGIS, CGAS, GUCY1A1 MEN1 2447/4885KMT2A 4250/4885SIGMAR1 1325/4885
US-12077611-B2 Cyclic peptides multimers targeting α4β7 integrin ITGB7, ITGB4, ITGA4 MEN1 1768/4885KMT2A 4279/4885SIGMAR1 2470/4885
US-11840581-B2 α4β7 thioether peptide dimer antagonists EPCAM, SELPLG, VCAM1 MEN1 1809/4885KMT2A 3166/4885SIGMAR1 1389/4885
US-20240209026-A1 A4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS EPCAM, ANXA7, GRB7 MEN1 1673/4885KMT2A 4248/4885SIGMAR1 2607/4885
US-20230406884-A1 CYCLIC PEPTIDES MULTIMERS TARGETING ALPHA-4-BETA-7 INTEGRIN ITGB7, ITGB4, ITGA4 MEN1 1248/4885KMT2A 4390/4885SIGMAR1 1984/4885
US-20140256706-A1 BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME BRD4, BRDT, BRD3 MEN1 3205/4885KMT2A 337/4885SIGMAR1 4451/4885
US-11713338-B2 Cyclic peptides multimers targeting α-4-β-7 integrin ITGB7, ITGB4, ITGA4 MEN1 1389/4885KMT2A 4318/4885SIGMAR1 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.